Standard BioTools Inc. filings document the regulatory record for a life-science research tools company centered on mass cytometry, microfluidics, genomics, single-cell proteomics and spatial proteomics. Current reports cover operating results, revenue outlook disclosures, restructuring and cost-savings actions, capital-structure changes, material agreements and risk factors tied to its research-use instrument, consumable and service portfolio.
Proxy materials describe board elections, executive compensation votes, auditor ratification, equity incentive plan approvals and employee stock purchase plan amendments. Form 8-K filings also record material events such as the completed SomaLogic sale, related financial disclosures, shareholder voting matters and Nasdaq continued-listing compliance notices.
Standard BioTools (LAB) supplemented its definitive proxy statement for the proposed merger with Treeline Biosciences ahead of the November 19, 2026 stockholder meeting. Centerview’s discounted cash-flow analysis of Treeline, as of June 30, 2026, produced an implied equity value of $3,040 million to $4,205 million, or $15.88 to $21.89 per share. UBS’s separate analysis, also as of June 30, 2026, produced $2,638 million to $3,313 million, or $13.59 to $17.07 per share.
The supplement also reports Centerview’s Standard BioTools liquidation analysis at approximately $468,000,000 in implied equity value, or $1.14 per share. Under the proposed agreement, Merger Sub would merge with and into Treeline, which would survive as Standard BioTools’ wholly owned subsidiary, subject to the agreement’s conditions.
Standard BioTools Inc. (LAB) supplemented its definitive proxy statement with updated descriptions of financial-advisor analyses for its proposed merger with Treeline Biosciences. The stockholder special meeting is scheduled for November 19, 2026; under the merger agreement, Treeline would survive as a wholly owned subsidiary if the merger closes under its terms and conditions.
Centerview’s liquidation analysis estimated Standard BioTools’ implied equity value at approximately $468 million, or $1.14 per share. For Treeline, Centerview reported $15.88–$21.89 per share using a discounted cash flow analysis with 12.0%–15.0% discount rates; UBS reported $13.59–$17.07 per share using 15.0%–17.0% discount rates and perpetuity growth rates from (30)% to 0%. Centerview’s analysis also included estimated cash, tax savings and net effects of future capital raising.
Standard BioTools Inc. (LAB) common stock is the subject of an amended ownership report by MAK Capital Fund LP, MAK Capital One LLC, and Michael A. Kaufman. Each reports beneficial ownership of 24,979,153 shares, or 6.3% of the class, as of September 30, 2026. The reporting persons report shared voting and dispositive power over all 24,979,153 shares, with zero sole voting or dispositive power. The percentage calculation uses 394,790,441 shares outstanding as of November 1, 2026.
Standard BioTools Inc. (LAB) director Thomas D. Carey purchased 75,000 shares of common stock at $0.6253 per share on November 5, 2026. The purchase was direct; his reported holdings afterward were 419,456 shares.
Standard BioTools (LAB) reported third-quarter 2026 revenue of $19.385 million and net income of $13.483 million, versus a $34.687 million net loss a year earlier. The quarter included a $14.977 million continuing-operations loss and $28.460 million income from discontinued operations. Nine-month net income was $113.793 million, including a $172.3 million pretax gain on the SomaScan sale.
Cash and cash equivalents were $267.487 million at September 30, 2026. Net cash used in operating activities was $63.069 million in the first nine months, versus $73.153 million a year earlier. Standard BioTools received $388.2 million in net cash consideration for SomaScan at closing.
The Treeline all-stock merger is expected to close in the fourth quarter of 2026; existing holders are expected to own approximately 16% and former Treeline holders 84% of the combined company on a fully diluted basis, subject to adjustment. Standard BioTools expects to declare one CVR per outstanding share; eligible net proceeds would be paid pro rata in combined-company shares over five years, capped at 76.0 million shares. The $5.5 million cash sale of mass cytometry to Element Biosystems, LLC remains subject to stockholder approval and merger completion; the microfluidics sale closed November 3, 2026.
Standard BioTools Inc. (LAB) announced on November 3, 2026, with ARCHIMED, an investment firm focused exclusively on healthcare, that the previously announced sale of its Microfluidics business to ARCHIMED had closed.
Separately, the company said its definitive proxy statement/prospectus for the proposed transaction with Treeline Biosciences was declared effective October 21, 2026, and first mailed to stockholders on or about that date.
Standard BioTools Inc. (LAB) completed the sale of its Microfluidics business to ARCHIMED, a healthcare-focused investment firm, on November 3, 2026.
The business is now named Biomark Scientific and will operate as a standalone business within ARCHIMED with the same dedicated team. It provides microfluidics tools for high-throughput, multi-assay genomics. Its Biomark X9 system is described as performing automated PCR, qPCR and NGS library preparation, with simultaneous profiling of multiple genomic assay readouts in a single run. Biomark Scientific plans to build on the business’s technology, expertise and customer relationships while expanding its capabilities.
Standard BioTools Inc. registers for resale by certain Treeline stockholders up to 1,551,769,528 shares of common stock, based on an estimated exchange ratio of 11.7157; the shares represent approximately 59% of common stock expected to be outstanding immediately after the merger. Standard BioTools will receive no proceeds from these resales and will bear registration costs; selling holders bear any commissions or discounts.
Following the proposed all-stock merger, former Treeline stockholders are expected to own approximately 84% and former Standard BioTools stockholders approximately 16% of the combined company on a fully diluted basis. The merger is subject to stockholder approval, including for a proposed 1-for-20 to 1-for-40 reverse split and a name change to Treeline Biosciences. Separately, Element is to acquire Standard BioTools’ mass cytometry business for $5.5 million on a cash-free and debt-free basis, subject to customary adjustments, stockholder approval and merger completion. The merger is expected to be accounted for as a reverse recapitalization with Treeline as accounting acquirer.
Standard BioTools Inc. (LAB) registers up to 537,687,757 shares of common stock for issuance in its proposed all-stock merger with Treeline Biosciences, Inc. and resale by certain Treeline stockholders; LAB will receive no proceeds from those resales. Merger Sub would merge into Treeline, which would survive as LAB’s wholly owned subsidiary, subject to stockholder approval of the share issuance and charter amendment. If completed, LAB will change its name to Treeline Biosciences, Inc.; a 1-for-20 to 1-for-40 reverse stock split would occur at the effective time if not effected earlier, at a final ratio the companies mutually agree.
After closing, former LAB stockholders are expected to own approximately 16% and former Treeline stockholders approximately 84% of the combined company on a fully diluted basis, subject to adjustment for closing net cash. LAB expects to declare one contingent value right per outstanding share held on the last business day before the effective time. Payments would be based on specified net proceeds over a five-year term; no payments are assured, and issuance is capped at 76,000,000 shares of combined-company common stock. The mass cytometry sale to Element requires stockholder approval and merger completion. The special meeting is scheduled for November 19, 2026.